Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02457598
Recruitment Status : Active, not recruiting
First Posted : May 29, 2015
Last Update Posted : December 23, 2021
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences

Brief Summary:

The primary objectives of this study are to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of tirabrutinib (ONO/GS-4059) in combination with other targeted anti-cancer therapies and to evaluate the long-term safety of tirabrutinib as a monotherapy and in combination with other targeted anti-cancer therapies in adults with relapsed or refractory B-cell lymphoproliferative malignancies.

This study consists of three parts: Dose Escalation, Dose Expansion, and Long-term Safety Monitoring. During the Dose Escalation phase, participants will be sequentially enrolled in a standard 3 + 3 dose escalation study design, to receive oral tirabrutinib combined with idelalisib entospletinib +/- obinutuzumab. The Dose Expansion Phase will enroll additional participants with a single B-cell lymphoproliferative malignancy disease type to further evaluate efficacy, safety, tolerability, PK, and pharmacodynamics. The Long-term Safety Monitoring phase will evaluate the long-term safety of tirabrutinib both as a monotherapy and in combination with other anti-cancer therapies. As of Amendment 9, all participants currently on the study who have no clinical evidence of disease progression will transition into long-term safety monitoring. Participants from the ongoing Study GS-US-401-1787 and participants who came off Study GS-US-401-1757 and Study GS-US-401-1787 but continued to receive treatment via named patient use (or individual expanded use) will be enrolled into the long-term safety monitoring group (Group VI). Participants enrolled in Group VI will continue the same treatment regimen in Study GS-US-401-1787 or named patient use (or individual expanded use). As of Protocol Amendment 8, the maximum treatment duration for any participant is an additional 6 years from the date of this amendment (ie. until November 2025). As of Amendment 9, entospletinib will be provided until 31 December 2020 to participants who are currently receiving entospletinib. Participants treated with entospletinib as part of a combination regimen with tirabrutinib will stop receiving entospletinib by 31 December 2020 but may continue to be treated with tirabrutinib monotherapy. Idelalisib will be provided as 50 mg tablets until 31 December 2020 and 100 mg tablets until study completion. Participants assigned to the 50 mg tablet will be given the option, at the investigator's discretion, to switch to 100 mg once daily idelalisib dose.


Condition or disease Intervention/treatment Phase
B-cell Malignancies Drug: Tirabrutinib Drug: Idelalisib Drug: Entospletinib Drug: Obinutuzumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 202 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib (ONO/GS-4059) in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies
Actual Study Start Date : June 16, 2015
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Idelalisib

Arm Intervention/treatment
Experimental: Tirabrutinib + Idelalisib (Combination I)

Dose Escalation:

Participants will receive a single dose of tirabrutinib on Day 1 of Cycle 1 and tirabrutinib 20 mg + idelalisib 50 mg on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib 20 mg + idelalisib 50 mg. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled and administered escalating dose of tirabrutinib up to 160 mg + idelalisib up to 100 mg to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.

Dose Expansion:

Additional participants will receive tirabrutinib + idelalisib for an additional 6 years from the date of Protocol Amendment 8.

Drug: Tirabrutinib
Capsules or tablets administered orally
Other Name: ONO/GS-4059

Drug: Idelalisib
Tablets administered orally twice daily
Other Names:
  • Zydelig®
  • GS-1101
  • CAL-101

Experimental: Tirabrutinib + Entospletinib (Combination II)

Dose Escalation:

Participants will receive a single dose of tirabrutinib 40 mg on Day 1 of Cycle 1 and tirabrutinib 40 mg + entospletinib 200 mg on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib 40 mg + entospletinib 200 mg. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled and administered escalating dose of tirabrutinib up to 160 mg + entospletinib up to 400 mg to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.

Dose Expansion:

Additional participants will receive tirabrutinib + entospletinib for an additional 6 years from the date of Protocol Amendment 8.

Drug: Tirabrutinib
Capsules or tablets administered orally
Other Name: ONO/GS-4059

Drug: Entospletinib
Tablets administered orally
Other Name: GS-9973

Experimental: Tirabrutinib + Idelalisib + Obinutuzumab (Combination III)

Dose escalation:

Participants will receive tirabrutinib + idelalisib + obinutuzumab 1000 mg at 8 doses (tirabrutinib and idelalisib doses will depend on results of Combination I data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.

Dose Expansion:

Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for an additional 6 years from the date of Protocol Amendment 8.

Drug: Tirabrutinib
Capsules or tablets administered orally
Other Name: ONO/GS-4059

Drug: Idelalisib
Tablets administered orally twice daily
Other Names:
  • Zydelig®
  • GS-1101
  • CAL-101

Drug: Obinutuzumab
Administered intravenously

Experimental: Tirabrutinib + Entospletinib + Obinutuzumab (Combination IV)

Dose escalation:

Participants will receive tirabrutinib + entospletinib + obinutuzumab 1000 mg at 8 doses (tirabrutinib and entospletinib doses will depend on results of Combination II data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.

Dose Expansion:

Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for an additional 6 years from the date of Protocol Amendment 8.

Drug: Tirabrutinib
Capsules or tablets administered orally
Other Name: ONO/GS-4059

Drug: Entospletinib
Tablets administered orally
Other Name: GS-9973

Drug: Obinutuzumab
Administered intravenously

Experimental: Single Agent Tirabrutinib (Combination V)
Participants with relapsed or refractory chronic lymphocytic leukemia (CLL) may be enrolled to receive tirabrutinib 80 mg once daily.
Drug: Tirabrutinib
Capsules or tablets administered orally
Other Name: ONO/GS-4059




Primary Outcome Measures :
  1. Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) During the Dose Escalation Phase [ Time Frame: Up to 28 days ]
  2. Overall Response Rate (ORR) at Week 12 During the Dose Expansion Phase for Non-CLL Participants [ Time Frame: Week 12 ]
    Overall response rate (ORR) is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) as assessed by disease type.

  3. Overall Response Rate (ORR) at Week 24 During the Dose Expansion Phase for CLL Participants [ Time Frame: Week 24 ]
    Overall response rate (ORR) is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) as assessed by disease type.

  4. Percentage of Participants Experiencing Treatment-Emergent Adverse Events for the Long-term Safety Phase [ Time Frame: Up to 6 years from the date of Protocol Amendment 8 ]

Secondary Outcome Measures :
  1. Overall Response Rate (ORR) During the Dose Escalation Phase and Dose Expansion Phase [ Time Frame: Up to 6 years from the date of Protocol Amendment 8 ]
  2. Progression Free Survival (PFS) During the Dose Escalation Phase and Dose Expansion Phase [ Time Frame: Up to 6 years from the date of Protocol Amendment 8 ]
    PFS is defined as the interval from the start of the study therapy to the earlier of the first documentation of definite disease progression or death from any cause.

  3. Duration of Response (DOR) During the Dose Escalation Phase and Dose Expansion Phase [ Time Frame: Up to 6 years from the date of Protocol Amendment 8 ]
  4. Time to Response (TTR) During the Dose Escalation Phase and Dose Expansion Phase [ Time Frame: Up to 6 years from the date of Protocol Amendment 8 ]
  5. For Participants with Chronic Lymphocytic Leukemia (CLL) Only: Proportion of Participants who Achieve Minimal Residual Negative Disease (< 1 leukemia cell/10,000 leukocytes) During the Dose Escalation Phase and Dose Expansion Phase [ Time Frame: Up to 6 years from the date of Protocol Amendment 8 ]
  6. Plasma Pharmacokinetic (PK) Parameter: AUCtau of tirabrutinib, Idelalisib, Idelalisib Metabolite GS-563117, and Entospletinib During the Dose Escalation Phase and Dose Expansion Phase [ Time Frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12 (optional), 24 hours postdose ]
    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

  7. Plasma Pharmacokinetic (PK) Parameter: Cmax of tirabrutinib, Idelalisib, Idelalisib Metabolite GS-563117, and Entospletinib During the Dose Escalation Phase and Dose Expansion Phase [ Time Frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12 (optional), 24 hours postdose ]
    Cmax is defined as the maximum observed concentration of drug.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Diagnosis of follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL) (meeting International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Criteria 2008), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), or non-germinal center B-cell lymphoma (GCB) diffuse large B-cell lymphoma (DLBCL) as documented by medical records on World Health Organization (WHO) criteria
  • Prior treatment for FL, MZL, SLL, MCL, WM with ≥ 2 or for CLL or non-GCB DLBCL ≥ 1 chemotherapy-based or immunotherapy-based regimen, and not transplant eligible and have had either progressive disease (PD) or no response to previous treatment
  • For diseases other than Waldenstrom's macroglobulinemia (WM), presence of radiographically measurable presence of ≥ 1 lesion that measures ≥ 2.0 cm in the longest dimension (LD) and ≥ 1.0 cm in the longest perpendicular dimension (LPD)
  • Eastern Cooperative Oncology Group (ECOG) ≤ 2
  • Platelets ≥ 50 x 10^9/L; Hb ≥ 8.0 g/dL; absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L
  • Without transfusion and growth factors within 7 days
  • Aspartate transaminase/alanine transaminase (AST/ALT) ≤ 2.5 x upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 x ULN
  • Creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min
  • Not pregnant
  • Willingness and ability to comply with protocol-specified Pneumocystis jirovecii pneumonia (PJP) prophylaxis
  • Long-term Safety Monitoring group only (Group VI):

    • Currently enrolled in Study GS-US-401-1787 or previously enrolled in Study GS-US-401-1757 or Study GS-US-401-1787 and currently receiving continued treatment via named patient use
    • Continuing to benefit from the current treatment regimen in the opinion of the investigator/treating physician

Key Exclusion Criteria:

  • Hepatitis B surface antigen (HBsAG) positive or hepatitis B core antibody positive
  • Hepatitis C virus (HCV) antibody positive
  • History of long QT syndrome or whose corrected QT(QTc) interval measured (Fridericia method) at screening is prolonged (>450 ms)
  • Long-term Safety Monitoring group only (Group VI):

    • Evidence of clinical or radiological disease progression

Note: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02457598


Locations
Layout table for location information
United States, District of Columbia
Georgetown University Medical Center
Washington, District of Columbia, United States, 20007
United States, Indiana
Indiana University Health Goshen Center for Cancer Care
Goshen, Indiana, United States, 46506
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
France
CHRU de Lille, Hopital Claude Huriez
Lille, France, 59037
Hopital Saint Eloi
Montpellier, France, 34295
Chu Haut Leveque
Pessac, France, 33604
Centre Hospitalier de Lyon Sud
Pierre Benite, France, 69310
Institut Universitaire du Cancer-Oncopole I.U.C.T-O
Toulouse, France, 3110
United Kingdom
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom, CB20QQ
Cardiff and Vale Health Board, Clinical Research Facility
Cardiff, United Kingdom, CF14 4XW
Leeds Teaching Hosptials NHS Trust, Dept of Haematology
Leeds, United Kingdom, LS9 7TF
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom, LE1 5WW
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX
Plymouth Hospitals NHS Trust
Plymouth, United Kingdom, PL68DH
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom, SO16 6YD
Sponsors and Collaborators
Gilead Sciences
Investigators
Layout table for investigator information
Study Director: Gilead Study Director Gilead Sciences
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT02457598    
Other Study ID Numbers: GS-US-401-1757
2015-000834-30 ( EudraCT Number )
First Posted: May 29, 2015    Key Record Dates
Last Update Posted: December 23, 2021
Last Verified: December 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Obinutuzumab
Idelalisib
Antineoplastic Agents, Immunological
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action